Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
MacroGenics Inc.

Start price
Target price
Perf. (%)
€14.88
05.12.21
-
05.12.22
0.47%
12.12.21

Risky Investment
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€147.98
05.12.21
-
05.12.22
-23.17%
07.01.22

Could be worthwhile Investment >10% per year
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€42.42
03.12.21
-
03.12.22
7.50%
11.12.21

Risky Investment
buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€4.62
03.12.21
-
03.12.22
0.84%
11.12.21

Could be worthwhile Investment >10% per year
Krystal Biotech

Start price
Target price
Perf. (%)
€66.00
01.12.21
€50.00
31.12.23
16.67%
08.05.23

Could be very worthwhile Investment >20% year
buy
Ardelyx Inc.

Start price
Target price
Perf. (%)
€0.99
30.11.21
€1.00
30.11.22
36.36%
11.12.21

Could be very worthwhile Investment >20% year
Good culture
Innovative
Few uniques
buy
Athersys Inc.

Start price
Target price
Perf. (%)
€23.38
30.11.21
€25.00
30.11.22
-71.89%
07.07.22

Could be worthwhile Investment >10% per year
Innovative
Few uniques
Krystal Biotech

Start price
Target price
Perf. (%)
€77.00
29.11.21
-
29.11.22
-19.48%
10.12.21

Probably not worthwhile Investment
Acorda Therapeutics Cdt

Start price
Target price
Perf. (%)
€2.64
28.11.21
-
28.11.22
-77.46%
29.11.22

Risky Investment
buy
Inovio Pharma

Start price
Target price
Perf. (%)
€6.45
27.11.21
€3.30
27.11.22
-52.69%
12.04.22

Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
buy
Codexis Inc.

Start price
Target price
Perf. (%)
€33.00
23.11.21
-
23.11.22
-46.36%
02.03.22

Axsome Therapeutics Inc

Start price
Target price
Perf. (%)
€32.27
16.11.21
€25.00
16.11.22
59.84%
16.11.22

Could be very worthwhile Investment >20% year
buy
Kezar Life Sciences

Start price
Target price
Perf. (%)
€10.20
16.11.21
€11.00
31.12.24
0.98%
28.06.22

Could be very worthwhile Investment >20% year
Curis Inc.

Start price
Target price
Perf. (%)
€5.06
14.11.21
-
14.11.22
-83.10%
15.11.22

Probably not worthwhile Investment
buy
Apellis Pharmaceuticals

Start price
Target price
Perf. (%)
€37.80
13.11.21
€50.00
31.12.23
11.71%
29.06.22

Could be very worthwhile Investment >20% year
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€145.98
11.11.21
€75.00
11.11.22
-63.74%
11.04.22

Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float
buy
Avenue Therapeutics Inc.

Start price
Target price
Perf. (%)
€16.95
11.11.21
€30.00
11.11.22
-21.68%
14.12.21

Could be worthwhile Investment >10% per year
buy
EyePoint Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€13.70
09.11.21
€20.00
09.11.22
-62.04%
09.11.22

Could be very worthwhile Investment >20% year
buy
Staar Surgical Co.

Start price
Target price
Perf. (%)
€103.15
08.11.21
-
08.11.22
-29.38%
21.07.22

buy
Enanta Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€85.00
05.11.21
€100.00
31.12.23
-63.76%
08.05.23

Could be very worthwhile Investment >20% year
buy
Codexis Inc.

Start price
Target price
Perf. (%)
€34.80
05.11.21
€50.00
31.12.23
-79.99%
07.09.22

Could be very worthwhile Investment >20% year
buy
Revance Therapeutics Inc.

Start price
Target price
Perf. (%)
€12.40
01.11.21
€15.00
01.11.22
79.03%
02.11.22

Could be worthwhile Investment >10% per year
Krystal Biotech

Start price
Target price
Perf. (%)
€42.60
30.10.21
€37.00
30.11.22
54.93%
01.12.21

Could be very worthwhile Investment >20% year
buy
Otonomy Inc.

Start price
Target price
Perf. (%)
€1.67
25.10.21
€3.00
31.12.23
21.68%
28.06.22

Could be very worthwhile Investment >20% year
Novavax Inc.

Start price
Target price
Perf. (%)
€117.42
20.10.21
€105.00
20.10.22
24.32%
11.11.21

Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float